AMRN; a Q3 Pick and Possible Run-Up
For Q3 2018, one of our picks is AMRN as a run-up play before data read-out. They have an approved drug for cardiovascular health and...
${alertText}
Want unlimited access? Try Pro free for 7 days.
AMRN; a Q3 Pick and Possible Run-Up
ASCO 2018 Amp Noteworthy Abstracts
NBRV down 16.6% Today - Market Remains Tough on Companies Developing New Antibiotics
AACR 2018 Amp Up
Big/Suspected Movers FAQ/User Guide
Quarterly Big Mover Biotech Stocks To Watch
Q2 2023 Product Revenue Analyses
BPIQ Q2 2023 Biotech Hedge Fund (13F) Analysis
SYFOVRE (APLS) vs. IZERVAY (Astellas)
BIIB & SAGE: Zuranolone
Apellis Pharmaceuticals (APLS)
Our platform helps you uncover your next biotech investment opportunity